Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Biotechnology

Biotech

A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway

By Damian Garde

Heavyweights

Near the campus cow pasture, a scientist works to grow human organs — in pigs

By Usha Lee McFarling

advertisement

Biotech

FDA approves a game-changing treatment for blood cancer

By Damian Garde

advertisement

Biotech

Ignyta drug targeting rare lung cancer shows early promise, even when tumors spread to brain

By Adam Feuerstein

First Opinion

The rise of artificial intelligence means doctors must redefine what they do

By Bryan Vartabedian

In the Lab

CAR-T cancer therapy is potent, but can be lethal. New research helps explain why

By Meghana Keshavan

Opinions Plus

From the C-Suite: Biotech execs share their best interview questions — and the answers they want to hear

By STAT staff

advertisement

The Pharmalot View

Here’s how a loophole in a transparency law can distort medical practices

By Ed Silverman

advertisement

In the Lab

This tech won the Nobel Prize — and drug developers are avidly putting it to use

By Andrew Joseph

Pharmalot

Biotech execs still fret about pressure to bring down drug prices — but fears are starting to ease

By Ed Silverman

Health

A drug with the startling power to mute defective genes raises hopes for a new class of therapies — but hurdles abound

By Meghana Keshavan

Business

The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter

By Adam Feuerstein

Biotech

The big names at this startup have big plans to speed drug discovery — with ‘CRISPRomics’

By Meghana Keshavan

Business

Q&A: Biotech analysts explain which CEOs know their stuff & why pharma should be wary of a friendly FDA

By Adam Feuerstein and Damian Garde

Biotech

Axovant failed. Now what? A collection of takes hot and cold

By Damian Garde and Adam Feuerstein

Biotech

FDA rips into PTC’s Duchenne muscular dystrophy drug as advisory panel looms

By Adam Feuerstein

Biotech

The next big Alzheimer’s trial? Not until 2019. Here’s what’s in the works

By Damian Garde

Biotech

Another Alzheimer’s failure: Axovant’s drug flops in late-stage trial

By Damian Garde

Business

Pfizer spends billions to develop new drugs. It’s not satisfied. So it’s launching a startup

By Damian Garde

Biotech

Intercept stock rides a roller coaster after FDA note on Ocaliva

By Damian Garde

Biotech

Just months after expanding, biotech incubator LabCentral growing again

By Jonathan Saltzman

Business

Why too few women in life sciences is bad for business

By Shirley Leung

Adam's Take

Here’s why Alnylam stock took off like a rocket, stunning (and delighting) investors

By Adam Feuerstein

Biotech

A biotech scorecard: Taking stock of the industry’s make-or-break September

By Damian Garde

Biotech

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

By Adam Feuerstein

Biotech

The Biotech Devil’s Dictionary: Your guide to the inanities of industry jargon

By Damian Garde

Business

Commercial launch of Portola’s new blood thinner could be threatened by new clinical guidelines

By Adam Feuerstein

Business

Moderna leaves key questions unanswered as investors seek the reality behind the hype

By Damian Garde

Business

Alexion cutting 600 jobs and moving headquarters in major shakeup

By Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Leave this field empty if you're human:

Sign up for our morning rounds newsletter

Leave this field empty if you're human:

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
STAT Wunderkinds
Awards for STAT
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X